Neochem Bio Solutions IPO Details: Price, Dates & Financials
The Neochem Bio Solutions IPO is a closed SME Bookbuilding offer (Fresh Capital) that opened on 2 December 2025. The Neochem Bio Solutions IPO closed on 4 December 2025, with an issue price of ₹98 per share. The Neochem Bio Solutions IPO has a face value of ₹10 and a lot size of 1,200 shares. The Neochem Bio Solutions IPO is listed on 9 December 2025. The Neochem Bio Solutions IPO allotment was scheduled for 5 December 2025.
On the financial front, the Neochem Bio Solutions IPO reported revenue of ₹47 crore for 30 Sep 2025, compared with ₹86 crore for 31 Mar 2025. The Neochem Bio Solutions IPO PAT was ₹5 crore against ₹8 crore. The Neochem Bio Solutions IPO EBITDA stood at ₹9 crore with a 15.58% margin. The Neochem Bio Solutions IPO net worth as of 30 Sep 2025 was ₹32 crore.
Always verify The Neochem Bio Solutions IPO details and GMP data with the official offer document before investing in the Neochem Bio Solutions IPO.
Financial Summary
Amount in ₹ Crore
Metric
30 Sep 2025
31 Mar 2025
31 Mar 2024
Total Assets
96
79
64
Revenue
47
86
62
PAT
5
8
2
EBITDA
9
13
6
Net Worth
32
20
12
Reserves
20
13
5
Total Borrowing
39
36
33
Neochem Bio Solutions IPO Financials FAQs
Revenue of Neochem Bio Solutions (Amount in ₹ Crore) — 30 Sep 2025: 47; 31 Mar 2025: 86; 31 Mar 2024: 62. Profit after tax (PAT) — 30 Sep 2025: 5; 31 Mar 2025: 8; 31 Mar 2024: 2.
EBITDA of Neochem Bio Solutions (Amount in ₹ Crore) — 30 Sep 2025: 9; 31 Mar 2025: 13; 31 Mar 2024: 6. The EBITDA margin is 15.58%.
Total assets — 30 Sep 2025: 96; 31 Mar 2025: 79; 31 Mar 2024: 64. Net worth — 30 Sep 2025: 32; 31 Mar 2025: 20; 31 Mar 2024: 12. Reserves & surplus — 30 Sep 2025: 20; 31 Mar 2025: 13; 31 Mar 2024: 5. (Amount in ₹ Crore)
Total borrowing of Neochem Bio Solutions (Amount in ₹ Crore) — 30 Sep 2025: 39; 31 Mar 2025: 36; 31 Mar 2024: 33. Debt-to-equity ratio: 1.80.
The financials shown for Neochem Bio Solutions IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
